| Autor: |
Chen, M. F., Yang, T. T., Yeh, L. R., Chung, H. H., Wen, Y. J., Lee, W. J., Cheng, J. T. |
| Předmět: |
|
| Zdroj: |
Hormone & Metabolic Research; Apr2012, Vol. 44 Issue 4, p268-272, 5p |
| Abstrakt: |
Allantoin, an active principle of the yam, belongs to the group of guanidinium derivatives and has been reported to lower plasma glucose in diabetic animals. Recent evidence indicates that activation of the imidazoline I 2B receptor (I 2B R) by guanidinium derivatives also increases glucose uptake; however, the effect of allantoin on I2BR is still unknown. Glucose uptake into cultured C 2 C12 cells was determined using 2-[14C]- deoxy- D -glucose as a tracer. The changes in 5'-AMP-activated protein kinase (AMPK) expression were also identified by Western blotting analysis. The allantoin-induced glucose uptake action was dose-dependently blocked by BU224, a specific I 2 R antagonist, in C 2 C 12 cells. Moreover, AMPK phosphorylation by allantoin was found to be dose-dependently increased in C 2 C 12 cells using AICAR treatment as a reference. In addition, both actions of allantoin, the increases in glucose uptake and AMPK phosphorylation, were dose-dependently attenuated by amiloride in C 2 C 12 cells. Moreover, compound C at concentrations sufficient to inhibit AMPK blocked the allantoin-induced glucose uptake and AMPK phosphorylation. Thus, we suggest that allantoin can activate I 2BR to increase glucose uptake into cells, and propose I2BR as a new target for diabetic therapy [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
